Cargando…

(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer

PURPOSE: (18)F-DCFPyL prostate-specific membrane antigen (PSMA) PET/CT is commonly applied to locate lesions of prostate cancer (PCa), but its diagnostic function of quantitative parameters is ignored. Our study evaluates the parameters of intraprostatic PSMA uptake in patients newly diagnosed with...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shuoming, Liu, Tiantian, Zhu, Ziqiang, Zhang, Lin, Qian, Subo, Fu, Hongliang, Cao, Qifeng, Kang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850639/
https://www.ncbi.nlm.nih.gov/pubmed/35186741
http://dx.doi.org/10.3389/fonc.2022.800904
_version_ 1784652643032891392
author Zhou, Shuoming
Liu, Tiantian
Zhu, Ziqiang
Zhang, Lin
Qian, Subo
Fu, Hongliang
Cao, Qifeng
Kang, Jian
author_facet Zhou, Shuoming
Liu, Tiantian
Zhu, Ziqiang
Zhang, Lin
Qian, Subo
Fu, Hongliang
Cao, Qifeng
Kang, Jian
author_sort Zhou, Shuoming
collection PubMed
description PURPOSE: (18)F-DCFPyL prostate-specific membrane antigen (PSMA) PET/CT is commonly applied to locate lesions of prostate cancer (PCa), but its diagnostic function of quantitative parameters is ignored. Our study evaluates the parameters of intraprostatic PSMA uptake in patients newly diagnosed with PCa and explores their predictive value in risk classification, which is similar to D’Amico criteria. MATERIALS AND METHODS: We quantified the maximal standardized uptake value (SUVmax), mean SUV (SUVmean), total lesion (TL)-PSMA, prostate/muscle (P/M) ratio of the primary tumor, and PSMA-derived tumor volume (PSMA-TV) from 62 patients with histologically proven PCa. Patients newly diagnosed with PCa were allocated into risk groups (at low, intermediate, and high risk, respectively) in accordance with D’Amico criteria. Afterwards, the five parameters mentioned above among three different risk groups were compared, and their predictive values in the risk classification of PCa were explored. RESULTS: Significantly decreased levels of SUVmax, SUVmean, TL-PSMA, and P/M ratio were observed in the risk groups of low or intermediate or both, compared with the high-risk group. However, only the P/M ratio significantly elevated in patients with intermediate risk [mean ± SD (median): 46.58 ± 9.74 (45.27), P = 0.042] or high risk [98.95 ± 38.83 (97.52), P < 0.001], compared with low-risk patients [12.33 ± 5.93 (9.81)]. When P/M ratio was used to distinguish between low-risk and intermediate-risk patients, its c-statistics was 0.660. On the other hand, when distinguishing between intermediate-risk and high-risk groups, the c-statistics of P/M ratio was 0.667. Finally, when P/M ratio was used to distinguish between low-risk and high-risk patients, the c-statistics was 0.969. P/M ratio had a positive correlation with prostate-specific antigen in all enrolled PCa patients. CONCLUSION: The quantitative parameters of (18)F-DCFPyL PET/CT, including SUVmax, SUVmean, and P/M ratio, might assist in distinguishing low-risk or intermediate-risk groups from the high-risk group. Of these parameters, P/M ratio appears to be the better promising parameter for risk classification of prostate cancer than SUVmax.
format Online
Article
Text
id pubmed-8850639
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88506392022-02-18 (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer Zhou, Shuoming Liu, Tiantian Zhu, Ziqiang Zhang, Lin Qian, Subo Fu, Hongliang Cao, Qifeng Kang, Jian Front Oncol Oncology PURPOSE: (18)F-DCFPyL prostate-specific membrane antigen (PSMA) PET/CT is commonly applied to locate lesions of prostate cancer (PCa), but its diagnostic function of quantitative parameters is ignored. Our study evaluates the parameters of intraprostatic PSMA uptake in patients newly diagnosed with PCa and explores their predictive value in risk classification, which is similar to D’Amico criteria. MATERIALS AND METHODS: We quantified the maximal standardized uptake value (SUVmax), mean SUV (SUVmean), total lesion (TL)-PSMA, prostate/muscle (P/M) ratio of the primary tumor, and PSMA-derived tumor volume (PSMA-TV) from 62 patients with histologically proven PCa. Patients newly diagnosed with PCa were allocated into risk groups (at low, intermediate, and high risk, respectively) in accordance with D’Amico criteria. Afterwards, the five parameters mentioned above among three different risk groups were compared, and their predictive values in the risk classification of PCa were explored. RESULTS: Significantly decreased levels of SUVmax, SUVmean, TL-PSMA, and P/M ratio were observed in the risk groups of low or intermediate or both, compared with the high-risk group. However, only the P/M ratio significantly elevated in patients with intermediate risk [mean ± SD (median): 46.58 ± 9.74 (45.27), P = 0.042] or high risk [98.95 ± 38.83 (97.52), P < 0.001], compared with low-risk patients [12.33 ± 5.93 (9.81)]. When P/M ratio was used to distinguish between low-risk and intermediate-risk patients, its c-statistics was 0.660. On the other hand, when distinguishing between intermediate-risk and high-risk groups, the c-statistics of P/M ratio was 0.667. Finally, when P/M ratio was used to distinguish between low-risk and high-risk patients, the c-statistics was 0.969. P/M ratio had a positive correlation with prostate-specific antigen in all enrolled PCa patients. CONCLUSION: The quantitative parameters of (18)F-DCFPyL PET/CT, including SUVmax, SUVmean, and P/M ratio, might assist in distinguishing low-risk or intermediate-risk groups from the high-risk group. Of these parameters, P/M ratio appears to be the better promising parameter for risk classification of prostate cancer than SUVmax. Frontiers Media S.A. 2022-02-03 /pmc/articles/PMC8850639/ /pubmed/35186741 http://dx.doi.org/10.3389/fonc.2022.800904 Text en Copyright © 2022 Zhou, Liu, Zhu, Zhang, Qian, Fu, Cao and Kang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhou, Shuoming
Liu, Tiantian
Zhu, Ziqiang
Zhang, Lin
Qian, Subo
Fu, Hongliang
Cao, Qifeng
Kang, Jian
(18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
title (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
title_full (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
title_fullStr (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
title_full_unstemmed (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
title_short (18)F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
title_sort (18)f-dcfpyl pet/ct in newly diagnosed prostate cancer: diagnostic value of intraprostatic psma uptake in risk classification of prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850639/
https://www.ncbi.nlm.nih.gov/pubmed/35186741
http://dx.doi.org/10.3389/fonc.2022.800904
work_keys_str_mv AT zhoushuoming 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT liutiantian 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT zhuziqiang 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT zhanglin 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT qiansubo 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT fuhongliang 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT caoqifeng 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer
AT kangjian 18fdcfpylpetctinnewlydiagnosedprostatecancerdiagnosticvalueofintraprostaticpsmauptakeinriskclassificationofprostatecancer